Most popular

WHAT IS MET gene amplification?

WHAT IS MET gene amplification?

Expand Collapse Gene Amplification in MET Gene amplification occurs when a region of DNA that contains a gene is duplicated, it is said to be “amplified”. As a result of MET amplification, there is an increased amount of the MET protein in cells than is normally found.

What does c-MET stand for?

Biomarker Abbreviation: c-MET. Definition: also known as mesenchymal epithelial transition factor (MET) or hepatocyte growth factor receptor (HGFR) – a proto-oncogene active in cell signaling, c-MET promotes cancer cell growth and multiplication.

What is the MET pathway?

c-MET is a receptor tyrosine kinase that, after binding with its ligand, hepatocyte growth factor, activates a wide range of different cellular signaling pathways, including those involved in proliferation, motility, migration and invasion.

Is c-MET the same as MET?

c-met or c-Met (all symbols written in italic!) is referred to the gene; in this case to a proto-oncogene because of the presence of “c-” in the symbol. MET is the abbreviation of Mesenchymal to Epithelial Transition (biological process).

What is MET NSCLC?

The hepatocyte growth factor receptor (MET) is a potential therapeutic target in a number of cancers, including NSCLC. In NSCLC, MET pathway activation is thought to occur through a diverse set of mechanisms that influence properties affecting cancer cell survival, growth, and invasiveness.

What does met stand for?

metabolic equivalent
MET stands for metabolic equivalent, which is one way that exercise physiologists estimate how many calories are burned during physical activity. Having a basic understanding of METs and how to use them can help you determine the best physical activities to help your clients achieve their health and fitness goals.

What chromosome is met on?

MET proto-oncogene (GeneID: 4233) has a total length of 125,982 bp, and it is located in the 7q31 locus of chromosome 7. MET is transcribed into a 6,641 bp mature mRNA, which is then translated into a 1,390 amino-acid MET protein.

What is MET in oncology?

MET is a tyrosine kinase receptor involved in cell proliferation, survival, and migration. MET pathway is activated in cancer by gene amplification and overexpression, ligand overexpression and autocrine/paracrine activation, and activating MET mutations.

How do you determine MET amplification?

Detection of MET amplification can be performed by several techniques such as Southern blot, polymerase chain reaction (PCR), and fluorescence in situ hybridization (FISH).

WHAT IS MET overexpression?

Mesenchymal–epithelial transition factor (MET) is the so called hepatocyte growth factor (HGF) receptor. MET overexpression and its gene amplification have recently been indicated as survival prognostic factors for many cancers including GC.

Who are NSCLC patients with MET gene amplification?

In addition, MET ( c-MET) gene amplification is another important mechanism and is detectable in approximately 5–22% of NSCLC patients with acquired resistance to first-generation EGFR-TKIs [ 2, 3, 4 ].

How is met expression and amplification in patients with cancer?

Methods: Tumor specimens from patients enrolled on a preoperative chemotherapy study (NCI 5700) were examined for the presence of MET gene amplification by FISH, MET mRNA expression by quantitative PCR, MET overexpression by immunohistochemistry (IHC), and for evidence of MET pathway activation by phospho-MET (p-MET) IHC.

Which is the best treatment for MET amplification?

MET amplification is associated with acquired resistance to EGFR tyrosine kinase inhibitor (TKI) therapy in patients with NSCLC and EGFR-activating mutations. Crizotinib (see NCCN guidelines) or other MET -targeted treatment may be considered in NSCLC cases with high-level MET amplification or MET exon 14 skipping mutation. 1

What kind of biomarker is MET amplification used for?

MET Amplification is a predictive biomarker for use of crizotinib, afatinib, dacomitinib, erlotinib, gefitinib, and osimertinib in patients. Of the therapies with MET Amplification as a predictive biomarker, 6 have NCCN guidelines in at least one clinical setting.